This editorial examines the development of synthetic peptide vaccines as alternatives to conventional vaccines. While the sequencing of pathogenic proteins raised hopes for vaccines against diseases like malaria and AIDS, progress has been disappointing due to incomplete understanding of immune responses. The author explains that effective vaccines must induce both humoral and cellular immunity. A key challenge is that most neutralizing epitopes are discontinuous and conformational, while short linear synthetic peptides cannot easily replicate these structures. However, some success has been achieved by constructing peptides that adopt tertiary conformations, such as a malaria vaccine showing 38.8% protective efficacy in field trials. Helper T-cell epitopes are linear and better suited to synthetic peptides, leading to the concept of chimeric peptides combining neutralizing and T-cell epitopes. Cytotoxic T-lymphocyte epitopes also show promise but require detailed structural understanding. The author concludes that while early optimism was naive, rational design incorporating conformational epitopes, understanding protein structure-function relationships, and multi-component approaches stimulating appropriate immune elements offers the most realistic path forward.

Key findings

• Most neutralizing epitopes are conformational and discontinuous, making short linear synthetic peptides inherently non-protective unless engineered to adopt tertiary structures
• Synthetic malaria vaccine with conformational epitopes showed 38.8% protective efficacy in Colombian field trials of 1,548 volunteers
• Chimeric peptide vaccines combining neutralizing B-cell epitopes, helper T-cell epitopes, and cytotoxic T-lymphocyte epitopes appear most promising
• Successful synthetic vaccines require detailed knowledge of pathogen protein structure and function, not just sequence information